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ABSTRAK
Tujuan: untuk menilai penggunaan angiogenesis, peradangan, jumlah trombosit, dan status metastasis 
sebagai prediktor risiko trombosis yang diwakili oleh tingkat P-selektin pada pasien karsinoma nasofaring (NPC). 
Metode: studi potong lintang dilakukan pada pasien karsinoma nasofaring (NPC) di poliklinik Hematologi 
dan Onkologi Klinik Rumah Sakit Cipto Mangunkusumo, Jakarta, pada Mei - Oktober 2012. Data mengenai 
angiogenesis (CD105 dan VEGFR-2), peradangan (IL-6), jumlah trombosit, dan status metastasis dinilai pada 
saat pendaftaran, serta tingkat P-selektin larut untuk semua pasien yang memenuhi syarat penelitian. Analisis 
bivariat dilanjutkan dengan analisis regresi linier berganda untuk mengidentifikasi prediktor independen tingkat 
P-selektin larut. Hasil: dilakukan analisis pada 60 pasien NPC yang terdaftar dalam penelitian ini. Terdapat 
korelasi antara jumlah trombosit (r=0,389; p=0,002), IL-6 (r=0,595; p<0,001) dan jumlah metastasis (r=0,542; 
p<0,001) dengan tingkat P-selektin larut. Analisis korelasi menunjukkan bahwa ketiga variabel tersebut dapat 
memprediksi tingkat P-selektin larut yang disesuaikan dengan R-kuadrat 65%. Tidak ditemukan korelasi antara 
VEGFR-2 dan CD105 dengan tingkat P-selektin larut. Kesimpulan: jumlah trombosit, IL-6, dan status metastasis 
dapat digunakan sebagai prediktor tingkat P-selektin larut sebagai parameter risiko trombosis pada pasien NPC.
Kata kunci: karsinoma nasofaring (NPC), risiko trombosis, P-selektin larut.
ABSTRACT
Aim: to assess the use of of angiogenesis, inflammation, platelets count, and metastatic status as predictors 
for thrombosis risk represented by soluble P-selectin level in nasopharyngeal carcinoma (NPC) patients. 
Methods: a cross sectional study was conducted on NPC patients at the Hematology and Oncology Clinic of 
Cipto Mangunkusumo Hospital, Jakarta, during Mei to October 2012. Data regarding angiogenesis (CD105 
and VEGFR-2), inflammation (IL-6), platelets count, and metastatic status were assessed at enrollment, as 
well as soluble P-selectin levels in all eligible patients. Bivariate analysis continued with multiple linear 
regression analysis were done to identify independent predictors for soluble P-selectin levels. Results: sixty 
NPC patients were enrolled in the study. There was correlation between platelet counts (r=0.389; p=0.002), 
IL-6 (r=0.595; p<0.001) and number of metastatic sites (r=0.542; p<0.001) with soluble P-selectin level, and 
a linear regression analysis showed that these three variables can predict soluble P-selectin levels with adjusted 
R-square 65%. There was no correlation between VEGFR-2 and CD105 levels with soluble P-selectin levels. 
Conclusion: platelet counts, IL-6 level, and number of sites of metastasis can be used as predictors of soluble 
P-selectin level as parameter of thrombosis risk in NPC patients.
Key words: nasopharyngeal carcinoma (NPC), thrombosis risk, soluble P-selectin.
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INTRODUCTION
Nasopharyngeal carcinoma (NPC) is 
an interesting cancer because of its defined 
geographic and racial distribution.1-5 It is a 
highly prevalent malignant disease in several 
regions such as Southern China, especially in 
the Guangdong Province and has the highest 
prevalence in the world with 20-40 cases per 105 
inhabitants. Recent data indicated intermediate 
incidence rates of NPC can be found in Southeast 
Asia, including Indonesia with 5.66 cases per 105 
inhabitants. Nasopharyngeal cancer is frequently 
found in Indonesia, rating as the fourth most 
common cancer after cervical cancer, breast 
cancer and lung cancer.6
Cancer is frequently complicated by the 
development of thrombosis. The incidence of 
thrombosis in cancer patients is 20%, and several 
risk factors have been described in recent studies 
and include tumor type, tumor stage, age, sex, 
racial, year of diagnosis, surgery, chemotherapy, 
and the use of erythopoiesis-stimulating agents. 
The patients with metastatic cancer who have 
the highest incidence of thrombosis are i.e., 
pancreatic, ovarian, renal, lung, and brain 
cancers.7-9 Recent studies showed the incidence 
of NPC with venous thromboembolism (VTE) 
to be 4.3%.
Thrombosis is promoted by angiogenesis 
and metastasis. Angiogenesis has the essential 
role in the formation of new vascular networks 
to support cancer growth, progression of cancer 
and metastasis in the head and neck cancer, 
including nasopharyngeal carcinoma (NPC). 
Angiogenesis induces activation of platelet and 
endothelial cell inflammation that stimulates 
the release of angiogenic factors and synthesis 
of interleukin-6 (IL-6) by macrophages and 
endothelial cells, increasing the incidence of 
thrombosis in cancer patients. Endothelial cells 
inflammation induce express tissue factors that is 
one of the key procoagulants, one of them being 
soluble P-selectin.10-13 Recent studies showed that 
while the levels of the human soluble P-selectin 
are more than equal to 53.1 ng/ml, implying that 
P-selectin can be used as a predictor of venous 
thromboembolism in cancer patients.
Angiogenic factors also include activator and 
inhibitor molecules that influence the angiogenic 
process. Other proteins have been identified such 
as the angiogenic activator, including vascular 
endothelial growth factor (VEGF), transforming 
growth factor (TGF), and interleukin. The 
VEGF and their receptors includes VEGFR-2 
and TGF and their receptors includes CD105 
are receiving increasingly more attention in the 
field of angiogenesis. Based on these studies, the 
existence of VEGFR-2 and CD105 in the blood 
of cancer patients could be used as angiogenic 
parameters.14
To reduce the mortality and morbidity 
from NPC caused by thrombosis, it is therefore 
important to identify potential predictors for 
thrombosis in NPC. This study was aimed to study 
the correlation of angiogenesis, inflammation, 
and metastatic status with thrombosis in NPC 
patients. The specific purpose in this study was 
to determine correlation between parameters 
(CD105, VEGFR-2, IL-6, platelet count and 
metastatic sites) with soluble P-selectin and to 
observe any potential parameters that could be 
used as predictors for thrombosis in NPC.
METHODS
A cross sectional study was conducted 
among nasopharyngeal (NPC) cancer patients 
who visited the Hematology and Oncology Clinic 
of Cipto Mangunkusumo Hospital, Jakarta, from 
May to October 2012. Patients were included in 
the study if they have histologically confirmed 
diagnosis of NPC and underwent NPC staging 
(nasopharyngeal CT-scan, chest x-ray and CT-
scan, and bone scan). Patients who recieved 
therapy before the enrollment, have systemic 
infection, active hemorrhagic, other malignant 
diseases, diabetes, end-stage renal disease, 
pregnant women, and were on antiplatelet and 
/ or anticoagulants were excluded from the 
study. The study protocol has been approved by 
Research Ethics Committee of the Faculty of 
Medicine, Universitas Indonesia.
Demographics data was confirmed by 
individual reports, while data regarding clinical, 
laboratory, radiographical, and histopathological 
examinations were obtained from patient’s 
medical records. Detection of CD105, VEGFR-2, 
IL-6, as well as soluble P-selectin was done using 
ELISA. Platelet count was performed by Sysmex 
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Analyzer XE-2000. 
Data regarding demographical and clinical 
characteristics was presented to describe study 
population. The correlations between CD105, 
VEGFR-2, IL-6 and platelets counts with 
soluble P-selectin were tested using Pearson’s 
correlation test, while the correlation between 
number of metastatic sites with soluble P-selectin 
was tested using Spearman’s correlation test 
in bivariate analysis. All predictors revealed 
p-value of <0.2 in bivariate analyses included in 
multivariate linear regression analysis to identify 
independent predictors for soluble P-selectin 
level. All statistical procedures were conducted 
using SPSS version 16.
RESULTS
Characteristics of Subject
During the study period, 60 patients met the 
eligibility criteria and were enrolled. Of the total 
number of patients, 45 (75%) of subjects were 
males with the mean age of subjects between 
43.9 (standard deviation +11.58) years old and 
most of them are in the 31-40 years age bracket. 
Demographical and clinical characteristics of 
study subjects are shown in Table 1.
Correlat ion between Angiogenesis , 
Inflammation, Platelet Counts, and Metastatic 
Status with Risk of Thrombosis
Table 2 shows the correlation between 
parameters of angiogenesis (CD105, VEGFR-2), 
inflammation (IL-6), platelet counts, dan 
metastatic status with risk of thrombosis (soluble 
P-selectin level) among study subjects.
Table 1. Characteristics of subject (N=60)
Characteristics N (%)
Age (years), mean (SD) 43.9 + 11.58
Age group
 - <20 years 2 (3.3%)
 - 20 – 30 years 4 (6.7%)
 - 31 – 40 years 17 (28.3%)
 - 41 – 50 years 15 (25%)
 - >50 years 22 (36.7%)
Stage
 - I – IVA 22 (36.8%)
 - IVB 19 (31.7%)
 - IVC 19 (31.7%)
Metastatic 19 (31.7%)
Hemoglobin levels (g/dL), mean (SD) 12.36 ± 2.04
Leukocyte count (per mm3),  
mean (SD) 11.38 ± 8.36
Platelets count (per mm3), mean (SD) 326.43 ± 108.47
Table 2. Coefficient correlation of predictors with soluble 
P-selectin




Platelet counts 0.39 <0.001
Number of 
metastasis sites 0.527 <0.001
Based on bivariate analyses above, we 
include all predictors in the multivariate linear 
regression analysis which revealed IL-6, 
platelet counts, and number of metastasis sites 
as independent predictors for soluble P-selectin 
level, with adjusted R2 of 0.65.
DISCUSSION
The diagnosis and treatment of NPC in 
Indonesia are not without their challenges. First 
of all, a large number (Table 1) of patients who 
present themselves at the clinic are at their peak 
of their productivity – ages younger than 50 
years – an age bracket which still has families to 
support. Secondly, another problem is the disease 
stage: more than 30% presented as metastatic 
disease. Stages I and II usually respond well to 
radiotherapy with / without chemotherapy but at 
present, current treatment of recurrent/metastatic 
disease has not been satisfactory.
Histopathologically, around 83.3% of cases 
proved to be undifferentiated carcinoma, or type 
III acoording to the WHO classification of NPC, 
with 15% WHO type II NPC tumors and 1.7% 
WHO type I NPC tumors. This is to compare 
with other studies in Singapore and China 
which reported NPC WHO type III as the most 
prevalent form.15,16
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The result of radiology examination showed 
that most specific metastatic sites of NPC are 
bone metastasis, followed by lungs, non regional 
lymph tissue, liver and central nervous system 
(84.2%, 5% and 3.3% incidence for non regional 
lymph, liver, and central nervous system). A 
number of studies had reported the same results 
for metastatic sites of NPC. It showed that bone 
had the highest incident metastatic sites in a 
Tunisian and Singaporean study.17,18 This study 
results showed around 52.6% of cases in bone 
metastasis was found in single bone metastasis 
sites followed by 47.4% incidence in multiple 
bone metastasis. NPC metastasis was more 
incidence in single organ and two organs with 
13.3% incidence than in three organs only found 
5% incidence. Metastatic sites was more found 
in NPC WHO type II and type III than NPC 
WHO type 1.
The aforementioned situation is compounded 
by the fact that cancer patients – NPC being one 
of them – have their treatment complicated by 
thrombosis. It is part of the cancer process and 
thrombosis in the form of lung embolism is the 
most common cause of death second only to the 
progression of the cancer.8
And not only are the types of cancer and 
stages are relevant in the thrombotic process, 
the cancer patient has also several risk factors 
predisposing to thrombosis its consequences, 
such as hospitalization and immobilization, the 
use of central catheters, and many comorbid 
conditions associated mainly in the elderly. It 
is thus very important that a marker – or set of 
markers – is found.
Using the ANOVA statistical test it was 
found that platelet count, interleukin-6 and 
metastatic status had a significant difference with 
sP-selectin. This result was the same as reported 
by Violetta et al where correlation between 
interleukin-6 and sP-selectin in the colorectal 
cancer patients had a significant difference. 
The regression linear test showed platelet 
count, interleukin-6 and metastatic status had a 
significantly influence sP-selectin with 67.1%. 
By using the same statistical test it was revealed 
that platelet counts influenced sP-selectin with 
38.9% or r=0.389, different from that reported 
by Ay et al (r=0.19).19
Based on these result, we found that 
interleukin-6, an inflammatory parameter, 
platelet count and metastatic status could be used 
as potential predictors for thrombosis in NPC 
because of the correlation with the expression of 
sP-selectin in humans. Generally, the results of this 
study was good enough as it was able to collect 60 
NPC patients and all of them were able to undergo 
testing for sP-selectin and platelet counts.
This study was as the first investigation 
aiming to measure sP-selectin, VEGFR-2, and 
CD105 in among NPC patients in Southeast Asia. 
As most patients were found at later stages of 
the disease, a larger sampling consisting of the 
whole spectrum of stages (I,II,II and IV) might 
provide better data and is on planning. It is hoped 
that future testing will include platelet activators 
and other factors contributing to the elucidation 
of sP-selectin, including leukocytes, lipid profiles 
and endothelial cells dysfunction. 
CONCLUSION
In this study, there was statistically significant 
correlation between interleukin-6, platelet count, 
and metastatic status with sP-selectin. VEGFR-2 
and CD105 had not a significant correlation 
with interleukin-6, sP-selectin, and metastatic 
status. So that, the combination of interleukin-6 
(inflammatory parameters), platelet count and 
metastatic status have the potential to predict 
the occurrence of thrombosis in NPC patients. 
It is hoped that these findings will contribute to 
the prevention of thrombosis in NPC patients.
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